Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16054907 | 0.91 | MAPK1 (0.58) | NAMPTMAPK1MEN1KMT2AKDM4E | |
| SCHEMBL22859045 | 0.86 | NAMPT (0.58) | NAMPTMEN1KMT2A | |
| SCHEMBL22859047 | 0.86 | NAMPT (0.58) | NAMPTMEN1KMT2A | |
| SCHEMBL22922423 | 0.86 | NAMPT (0.58) | NAMPTMEN1KMT2A | |
| SCHEMBL21590172 | 0.85 | NAMPT (0.63) | NAMPT | |
| SCHEMBL28906261 | 0.83 | NAMPT (0.56) | NAMPTMEN1KMT2A | |
| SCHEMBL12156536 | 0.83 | CA2 (0.57) | NAMPTMAPK1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL5115404 | 0.82 | CA2 (0.56) | NAMPTMAPK1KDM4EMAPTHIF1A | |
| SCHEMBL24331631 | 0.80 | CA2 (0.67) | NAMPTMEN1KMT2AKDM4EMAPT | |
| SCHEMBL24230349 | 0.79 | NAMPT (0.57) | NAMPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758511-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160168134-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-9296723-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2852585-A1 | NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-04-01 | — | — | EP | disclosed |
| US-20140336168-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2014-11-13 | — | — | US | disclosed |
| WO-2013170113-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168134-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | NAMPT 1/4885MAPK1 3544/4885MEN1 2691/4885 |
| US-20140336168-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | NAMPT 1/4885MAPK1 3544/4885MEN1 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.